MedKoo Cat#: 318886 | Name: Tolcapone
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tolcapone is a drug used to treat Parkinson's disease (PD). It is a selective, potent and reversible nitro catechol type inhibitor of enzyme catechol-O-methyl transferase (COMT).

Chemical Structure

Tolcapone
CAS#134308-13-7

Theoretical Analysis

MedKoo Cat#: 318886

Name: Tolcapone

CAS#: 134308-13-7

Chemical Formula: C14H11NO5

Exact Mass: 273.0637

Molecular Weight: 273.24

Elemental Analysis: C, 61.54; H, 4.06; N, 5.13; O, 29.28

Price and Availability

Size Price Availability Quantity
50mg USD 500.00
100mg USD 800.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Tolcapone, Tasmar, Ro 40-7592, SOM0226
IUPAC/Chemical Name
(3,4-dihydroxy-5-nitrophenyl)-(4-methylphenyl)methanone
InChi Key
MIQPIUSUKVNLNT-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3
SMILES Code
O=C(C1=CC([N+]([O-])=O)=C(O)C(O)=C1)C2=CC=C(C)C=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 273.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Truong DD. Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin Interv Aging. 2009;4:109-13. Epub 2009 May 14. Review. PubMed PMID: 19503773; PubMed Central PMCID: PMC2685232. 2: Pilipovich AA, Golubev VL. [Tolcapone in the management of Parkinson's disease]. Zh Nevrol Psikhiatr Im S S Korsakova. 2007;107(6):71-8. Review. Russian. PubMed PMID: 18688929. 3: Leegwater-Kim J, Waters C. Role of tolcapone in the treatment of Parkinson's disease. Expert Rev Neurother. 2007 Dec;7(12):1649-57. Review. PubMed PMID: 18052761. 4: Olanow CW, Watkins PB. Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol. 2007 Sep-Oct;30(5):287-94. Review. PubMed PMID: 17909307. 5: Konopka M, Członkowski A. [Comparison of the safety of the medicinal product in the European Union and the United States, tolcapone (Tasmar) -- COMT inhibitor as the analyzed example]. Neurol Neurochir Pol. 2005 Nov-Dec;39(6):490-6. Review. Polish. PubMed PMID: 16355307. 6: Borges N. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy. Drug Saf. 2003;26(11):743-7. Review. PubMed PMID: 12908845. 7: Borroni E, Cesura AM, Gatti S, Gasser R. A preclinical re-evaluation of the safety profile of tolcapone. Funct Neurol. 2001;16(4 Suppl):125-34. Review. PubMed PMID: 11996507. 8: Colosimo C. The rise and fall of tolcapone. J Neurol. 1999 Oct;246(10):880-2. Review. PubMed PMID: 10552233. 9: Jorga KM. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. Neurology. 1998 May;50(5 Suppl 5):S31-8. Review. PubMed PMID: 9591520. 10: Lees AJ. Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease. CNS Neurosci Ther. 2008 Spring;14(1):83-93. doi: 10.1111/j.1527-3458.2007.00035.x. Review. PubMed PMID: 18482101. 11: Stocchi F, De Pandis MF. Utility of tolcapone in fluctuating Parkinson's disease. Clin Interv Aging. 2006;1(4):317-25. Review. PubMed PMID: 18046910; PubMed Central PMCID: PMC2699640. 12: Leegwater-Kim J, Waters C. Tolcapone in the management of Parkinson's disease. Expert Opin Pharmacother. 2006 Nov;7(16):2263-70. Review. PubMed PMID: 17059382. 13: Borges N. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. Expert Opin Drug Saf. 2005 Jan;4(1):69-73. Review. PubMed PMID: 15709899. 14: Keating GM, Lyseng-Williamson KA. Tolcapone: a review of its use in the management of Parkinson's disease. CNS Drugs. 2005;19(2):165-84. Review. PubMed PMID: 15697329. 15: Micek ST, Ernst ME. Tolcapone: a novel approach to Parkinson's disease. Am J Health Syst Pharm. 1999 Nov 1;56(21):2195-205. Review. PubMed PMID: 10565698. 16: Guay DR. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Pharmacotherapy. 1999 Jan;19(1):6-20. Review. PubMed PMID: 9917075. 17: Avila A, Kulisevsky J. [Treatment of Parkinson's disease with COMT inhibitors: tolcapone]. Neurologia. 1998;13 Suppl 1:66-71. Review. Spanish. PubMed PMID: 9859687.